1
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
AMENDMENT NO. 3
TO
FORM 10-K
ANNUAL REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED COMMISSION FILE NUMBER
DECEMBER 31, 1996 0-23490
------------------------
VIVUS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 94-3136179
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER IDENTIFICATION NUMBER)
INCORPORATION OR ORGANIZATION)
545 MIDDLEFIELD ROAD, SUITE 200, MENLO PARK, CALIFORNIA 94025
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES AND ZIP CODE)
(415) 325-5511
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
------------------------
SECURITIES REGISTERED PURSUANT TO 12(B) OF THE ACT: NONE
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: COMMON STOCK, $.001
PAR VALUE
------------------------
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
As of February 28, 1997, the aggregate market value of the voting stock
held by non-affiliates of the Registrant was $632,342,107 (based upon the
closing sales price of such stock as reported by The Nasdaq Stock Market on such
date). Shares of Common Stock held by each officer, director, and holder of 5%
or more of the outstanding Common Stock on that date have been excluded in that
such persons may be deemed to be affiliates. This determination of affiliate
status is not necessarily a conclusive determination for other purposes.
As of February 28, 1997, the number of outstanding shares of the
Registrants' Common Stock was 16,426,606.
DOCUMENTS INCORPORATED BY REFERENCE
Certain information required by Items 6, 7 and 8 of Form 10-K is
incorporated by reference from the Registrant's annual report to security
holders furnished pursuant to Rule 14a-3 (the "Annual Report"). Certain
information required by Items 10, 11, 12 and 13 of Form 10-K is incorporated by
reference from the Registrant's proxy statement for the 1997 Annual
Stockholders' Meeting (the "Proxy Statement"), which will be filed with the
Securities and Exchange Commission within 120 days after the close of the
Registrant's fiscal year ended December 31, 1996.
================================================================================
2
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information required by this item is incorporated by reference from the
discussion in the Proxy Statement captioned "Record Date and Share Ownership."
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
This information required by this item is incorporated by reference from
the discussion in the Proxy Statement captioned "Certain Transactions and
Reports."
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENTS SCHEDULES AND REPORTS ON FORM 8-K
(a) The following documents are filed as part of this Report:
1. FINANCIAL STATEMENTS
Financial statements have been incorporated by reference to the
Registrant's Annual Report.
2. FINANCIAL STATEMENT SCHEDULES
Schedules have been omitted because the information required to be
set forth therein is not applicable or is shown in the consolidated financial
statements or notes thereto incorporated by reference herein.
3. EXHIBITS
NUMBER
------
# 3.1 Certificate of Incorporation of the Company, as currently in effect
3.2 Form of Amended and Restated Certificate of Incorporation of the Company,
to be filed immediately following the Company's Annual Meeting of
Stockholders if the stockholders approve Proposal 2 in the Company's Proxy
# 3.3 Bylaws of the Registrant, as amended
* 4.1 Specimen Common Stock Certificate of the Registrant
* 4.2 Registration Rights, as amended
** 4.3 Form of Agreement Not to Sell by and between the Registrant and certain
shareholders and option holders
* 4.4 Form of Preferred Stock Purchase Warrant issued by the Registrant to
Invemed Associates, Inc., Frazier Investment Securities, L.P. and Cristina
H. Kepner
+++ 4.5 Amended and Restated Preferred Shares Rights Agreement dated as of June 18,
1996, by and between Vivus, Inc. and First Interstate Bank of California,
including the Certificate of Designation, the form of Rights Certificate
and the Summary of Rights attached thereto as Exhibits A, B and C,
respectively
*+ 10.1 Assignment Agreement by and between Alza Corporation and the Registrant
dated December 31, 1993
*+ 10.2 Memorandum of Understanding by and between Ortho Pharmaceutical Corporation
and the Registrant dated February 25, 1992
* 10.3 Assignment by and between Ortho Pharmaceutical Corporation and the
Registrant dated June 9, 1992
*+ 10.4 License Agreement by and between Gene A. Voss, M.D., Allen C. Eichler,
M.D., and the Registrant dated December 28, 1992
*+ 10.5 License Agreement by and between Ortho Pharmaceutical Corporation and Kjell
Holmquist AB dated June 23, 1989
*+ 10.5B Amendment by and between Kjell Holmquist AB and the Registrant dated July
3, 1992
* 10.5C Amendment by and between Kjell Holmquist AB and the Registrant dated April
22, 1992
3
NUMBER
------
*+ 10.5D Stock Purchase Agreement by and between Kjell Holmquist AB and the
Registrant dated April 22, 1992
*+ 10.6A License Agreement by and between AMSU, Ltd., and Ortho Pharmaceutical
Corporation dated June 23, 1989
*+ 10.6B Amendment by and between AMSU, Ltd., and the Registrant dated July 3, 1992
* 10.6C Amendment by and between AMSU, Ltd., and the Registrant dated April 22,
1992
*+ 10.6D Stock Purchase Agreement by and between AMSU, Ltd., and the Registrant
dated July 10, 1992
* 10.7 Supply Agreement by and between Paco Pharmaceutical Services, Inc., and the
Registrant dated November 10, 1993
*+ 10.8 Agreement by and among Pharmatech, Inc., Spolana Chemical Works AS, and the
Registrant dated June 23, 1993
* 10.9 Master Services Agreement by and between the Registrant and Teknekron
Pharmaceutical Systems dated August 9, 1993
* 10.10 Lease by and between McCandless-Triad and the Registrant dated November 23,
1992, as amended
*** 10.11 Form of Indemnification Agreements by and among the Registrant and the
Directors and Officers of the Registrant
** 10.12 1991 Incentive Stock Plan and Form of Agreement, as amended
* 10.13 1994 Director Option Plan and Form of Agreement
* 10.14 Form of 1994 Employee Stock Purchase Plan and Form of Subscription
Agreement
* 10.15 Stock Restriction Agreement between the Company and Virgil A. Place, M.D.
dated November 7, 1991
* 10.16 Stock Purchase Agreement between the Company and Leland F. Wilson dated
June 26, 1991, as amended
* 10.17 Letter Agreement between the Registrant and Leland F. Wilson dated June 14,
1991 concerning severance pay
* 10.18 Letter Agreement between the Registrant and Paul C. Doherty dated January
26, 1994 concerning severance pay
** 10.19 Guaranteed Maximum Price Contract by and between the Registrant and
Marshall Contractors, Inc. dated January 27, 1995
** 10.20 Sub-sublease by and among the Registrant, Argonaut Technologies, Inc.,
ESCAgenetics Corp. and Tanklage Construction Co. dated January 31, 1995
#+ 10.21 Distribution Services Agreement between the Registrant and Synergy
Logistics, Inc. (a wholly-owned subsidiary of Cardinal Health, Inc.) dated
February 9, 1996
#+ 10.22 Manufacturing Agreement between the Registrant and CHINOIN Pharmaceutical
and Chemical Works Co., Ltd. dated December
###+ 10.23 Distribution and Services Agreement between the Registrant and Alternate
Site Distributors, Inc. dated July 17, 1996
##+ 10.24 Distribution Agreement made as of May 29, 1996 between the Registrant and
Astra AB
### 10.25 Menlo McCandless Office Lease made as of August 30, 1996 by and between
Registrant and McCandless - Triad
### 10.26 Sublease Agreement made as of August 22, 1996 by and between Registrant and
Plant Research Technologies
++ 10.27 Distribution Agreement made as of January 22, 1997 between the Registrant
and Janssen Pharmaceutica International, a division of Cilag AG
International
10.28 Lease Agreement made as of January 1, 1997 between the Registrant and
Airport Associates
4
NUMBER
------
10.29 Lease Amendment No. 1 as of February 15, 1997 between Registrant and
Airport Associates
10.30 Lease Agreement by and between 605 East Fairchild Associates, L.P. and
Registrant dated as of March 7, 1997
11.1 Computation of net loss per share
13.1 Portions of the 1996 Annual Report to Security Holders
** 16.1 Letter regarding change in independent public accountants
21.2 List of Subsidiaries
23.1 Consent of Independent Public Accountants
24.1 Power of Attorney (See "Power of Attorney")
27.1 Financial Data Schedule
- ---------------
* Incorporated by reference to the same-numbered exhibit filed with the
Registrant's Registration Statement on Form S-1 No. 33-75698, filed with
the Commission on February 24, 1996, as amended.
** Incorporated by reference to the same-numbered exhibit filed with the
Registrant's Registration Statement on Form S-1 No. 33-90390, filed with
the Commission on March 16, 1995, as amended.
*** Incorporated by reference to the same-numbered exhibit filed with the
Registrant's Form 8-B filed with the Commission on June 24, 1996
# Incorporated by reference to the same-numbered exhibit filed with the
Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31,
1996, as amended.
## Incorporated by reference to the same numbered exhibit filed with the
Registrant's Current Report on Form 8-K filed with the Commission on May 31,
1996, as amended.
### Incorporated by reference to the same-numbered exhibit filed with the
Registrant's Quarterly Report on Form 10-Q for the quarter ended September
30, 1996.
+++ Incorporated by reference to exhibit 99.1 filed with the Registrant's
Registration Statement on Form 8-A No. 0-23490, filed with the Commission
on June 24, 1996.
+ Confidential treatment granted.
++ Confidential treatment requested.
5
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized:
VIVUS, INC.,
a Delaware Corporation
By: /s/ DAVID C. YNTEMA
------------------------------------
David C. Yntema
Vice President of Finance and Chief
Financial Officer (Principal
Financial
and Accounting Officer)
Date: December 4, 1997